Asset profile
SAR442085
Biologic (subtype unspecified)
Evidence outlook · program status
Discontinued (2021), for reasons the sponsor has not stated
SAR442085 was Sanofi's Fc-engineered anti-CD38 antibody, a follow-on to Sarclisa, taken through a first-in-human study in relapsed/refractory multiple myeloma (NCT04000282). Sanofi's FY2021 20-F pipeline-changes table lists it under Removed with the reason 'Development discontinued' (the quote is that table's flattened row text), and the FY2022 20-F contains no occurrence of SAR442085. No reason beyond 'Development discontinued' is given. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
73 competitors in this universe: 13 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 73 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| SAR442085: this drug | Phase 1 | Biologic (subtype unspecified) | CD38 | ||
| Daratumumab | Approved | Monoclonal antibody | CD38 | ||
| Isatuximab | Approved | Monoclonal antibody | CD38 | ||
| BCD-264 | Phase 3 | Monoclonal antibody | CD38 | ||
| CT-P44 | Phase 3 | Monoclonal antibody | CD38 | ||
| HLX15 | Phase 3 | Monoclonal antibody | CD38 | ||
| Mezagitamab | Phase 3 | Monoclonal antibody | CD38 | ||
| QL2109 | Phase 3 | Monoclonal antibody | CD38 | ||
| SCTC21C | Phase 3 | Biologic (subtype unspecified) | CD38 | ||
| SG301 | Phase 3 | Monoclonal antibody | CD38 | ||
| TJ202 | Phase 3 | Monoclonal antibody | CD38 | ||
| CID-103 | Phase 1/2 | Monoclonal antibody | CD38 | ||
| CM313 | Phase 1/2 | Monoclonal antibody | CD38 | ||
| STI-6129 | Phase 1/2 | Antibody–drug conjugate | CD38 | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome |
…and 58 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
7 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.